Dry Eye Disease Clinical Trial
Official title:
Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation
Verified date | October 2017 |
Source | Tufts Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In vivo confocal microscopy (IVCM) is a sensitive imaging tool for detecting dry eye-associated subclinical inflammation. Studies have previously shown that IVCM provides an in vivo metric to measure inflammatory changes in the central cornea. The objective of the current study is to assess inflammatory response changes in the peripheral cornea and the conjunctiva by analyzing epithelial immune cell density and morphology in these areas and then correlating the IVCM findings to clinical signs and symptoms to establish novel objective imaging biomarkers.
Status | Completed |
Enrollment | 67 |
Est. completion date | July 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
For Dry Eye Disease Participants Inclusion Criteria: - Age >18 - Ability to consent to study - Symptoms of dry eye disease for at least 6 months, such foreign body sensation, burning, stinging, light sensitivity - Positive vital dye staining of the cornea - At least one of the following objective signs: (Schirmer I <10 mm at 5 minutes), decreased (<0.2 mm) tear meniscus, decreased tear breakup time (TBUT) of <10 seconds, positive vital dye staining of the conjunctiva For Age-Match Controls Inclusion Criteria: - Between the ages of 18-89 - The ability to provide informed consent for study inclusion - Clear, healthy cornea - Normal tear meniscus (> 0.3 mm) For Dry Eye Disease Participants Exclusion Criteria: - History of contact lens wear in the past 3 months - History of ocular surgery in the past 6 months - Active ocular allergies - History of ocular infection in the past 3 months - History of diabetes - History of topical or systemic anti-inflammatory therapy in the past 1 month For Age-Match Controls Exclusion Criteria: - History of ocular or eyelid surgery within the past 12 months - History of herpetic or other infectious keratitis or other inflammatory eye disease - History of any other acute ocular disease - Current use of topical medications (not including artificial tears) - Current use of contact lenses - History of ocular carcinoma or any recent ocular topical chemotherapy or radiotherapy - History of cancer elsewhere in the body which is currently under systemic chemotherapy - Current glaucoma disease requiring use of glaucoma drops - History of Diabetes mellitus - Current diagnosis of dry eye disease |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts Eye and Ear Infirmary | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Tufts Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peripheral Corneal Immune cell Status by IVCM | Peripheral Corneal Immune cell Status by IVCM • Density of dendritic immune cells • Density of non-dendritic immune cells • Morphology of immune cells | Visit 1 | |
Primary | Bulbar conjunctival immune cell Status by IVCM | Bulbar conjunctival immune cell Status by IVCM • Density of dendritic immune cells • Density of non-dendritic immune cells • Morphology of immune cells | Visit 1 | |
Secondary | Clinical Parameter: Ocular Surface Disease Index (OSDI) | Visit 1 | ||
Secondary | Clinical Parameter: Schirmer's II test | Visit 1 | ||
Secondary | Clinical Parameter: Conjunctival staining with lissamine green | Visit 1 | ||
Secondary | Clinical Parameter: Corneal staining with fluorescein | Visit 1 | ||
Secondary | Clinical Parameter: Tear Break Up Time (TBUT) | Visit 1 | ||
Secondary | Clinical Parameter: Conjunctival redness | Visit 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03216096 -
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT04656197 -
The Ocular Microbiome in Patients With Dry Eye Disease
|
||
Completed |
NCT05031806 -
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT03688802 -
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
|
Phase 2 | |
Completed |
NCT05213156 -
Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT04548427 -
Study to Evaluate the Efficacy and Safety of CKD-352
|
Phase 3 | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00395759 -
The Visual Effect of an Investigational Artificial Tear in the Tear Layer.
|
N/A | |
Completed |
NCT00680108 -
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
|
Phase 2 | |
Recruiting |
NCT06064071 -
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
Completed |
NCT01468168 -
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
|
Phase 2 | |
Completed |
NCT01014078 -
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT00799682 -
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
|
Phase 4 | |
Completed |
NCT05082974 -
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
|
Phase 3 | |
Recruiting |
NCT06146881 -
Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia
|
Phase 2 | |
Completed |
NCT03292809 -
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
|
Phase 2/Phase 3 |